Biomarkers and Precision Medicine in Upper Gastrointestinal Malignancies
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 5789
Special Issue Editor
Interests: immune-oncology; upper gastro-intestinal cancers; hepato-biliary cancers; pancreas cancer; esophagus cancer; gastric cancer; neuro-endocrine tumors; rare cancers; histopathology; precision medicine; targeted treatments; clinical trials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The current treatment of patients with upper gastrointestinal cancers is centred around chemotherapy and surgery, with a limited number of patients being candidates for immunotherapy or molecularly targeted treatment based on biomarker selection. The poor efficacy of treatment, late diagnoses, and the aggressive behavior of most cases contribute to the high mortality of these diseases.
To improve results, one major approach pursues the stratification of patients, according to the molecular characteristics for predicting treatment responses or resistance. Other strategies focus on novel biomarkers for early diagnosis, the detection of progression or relapse, or prognosis.
We invite researchers to publish studies within this topic in upper gastrointestinal malignancies, including esophageal-gastric, pancreatic, duodenal/small bowel, and hepatic–biliary cancers.
I look forward to receiving your contributions.
Prof. Dr. Morten Ladekarl
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- precision medicine
- molecular biology
- biomarker
- prognosis
- diagnosis
- esophagus cancer
- gastric cancer
- pancreatic cancer
- hepatocellular carcinoma
- cholangiocarcinoma
- duodenal cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.